[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618487":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":48,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University Hospital of North Norway","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Faecal microbiota transplantation (FMT)","EXPERIMENTAL","Single-group, single-centre, open-label. Intervention: Faecal microbiota transplantation administered via colonoscopy to the right side of the colon.",[13],"Biological: Biological: Preprocessed thawed donor FMT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Biological: Preprocessed thawed donor FMT","Biological: Preprocessed FMT solution is administered to the right side of the colon during a colonoscopy.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Mona Dixon Gundersen, MBChB, PhD","University Hospital of North Norway, Tromsø","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","+47 77798916","mona.dixon.gundersen@unn.no",[32],{"facility":24,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Tromsø","Troms","9016","Norway","NO",{"type":40,"coordinates":41},"Point",[42,43],18.95508,69.6489,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":29,"phoneExt":20,"email":30},"Dr Gundersen, MBChB",{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":6},"UiT The Arctic University of Norway","100618487","phase-1-alzheimers-disease-and-faecal-microbiota-transplantation--a-pilot-study-100618487",false,"NCT07332260","Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study","Alzheimer's Disease and Faecal Microbiota Transplantation","AD-FMT","Inclusion Criteria:\n\n* Alzheimer's dementia mild to moderate stage\n* Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024)\n* Capable of giving informed consent\n\nExclusion Criteria:\n\n* Contraindications for colonoscopy examination\n* Contraindications for Magnetic Resonance Imaging (MRI)\n* Life expectancy \\\u003C 1 year\n* Clinical frailty scale 7 or more\n* History of seizure disorder\n* History of brain tumour or intracranial bleed\n* Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder\n* Alcohol or substance abuse\n* Decompensated heart disease\n* Malignancy\n* Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin)\n* Pregnant or planning pregnancy\n* Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy\n* Status after colectomy or hemicolectomy\n* Inflammatory bowel disease\n* Immunocompromised individual\n* Receiving biological\u002Fantibody treatment","ALL","18 Years",{"count":64,"type":65},10,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.",[71,72],"Alzheimer s Disease","Faecal Microbiota Transplantation (FMT)",[74,75,76,77,78],"Alzheimer's disease","Dementia","Gut microbiota","faecal microbiota transplantation","FMT","2026-04-17",{"date":81,"type":82},"2026-04-22","ACTUAL",{"date":84,"type":65},"2026-05",{"date":86,"type":65},"2027-01",{"name":5,"class":6},1]